Neurocrine Biosciences NBIX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on trailing twelve months.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's return on equity?
- Neurocrine Biosciences (NBIX) reported return on equity of 22.5% in Q1 2026.
- How has Neurocrine Biosciences's return on equity changed year-over-year?
- Neurocrine Biosciences's return on equity increased by 81.1% year-over-year, from 12.4% to 22.5%.
- What is the long-term trend for Neurocrine Biosciences's return on equity?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's return on equity has grown at a -17.9% compound annual growth rate (CAGR), from 125.9% to 57.2%.
- What does return on equity mean?
- How much profit the company earns on the money shareholders have invested.
- How do you interpret return on equity?
- Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
- How does return on equity compare across companies?
- Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.